english.prescrire.org > Topics > Advancing healthcare policy > Advancing healthcare policy in Europe: a chronological recap of actions > 2016 Recap > The need for a critical review of the intellectual property system and incentives for medical innovation (6/2016)

Advancing healthcare policy

Advancing healthcare policy in Europe: a chronological recap of actions

A recap of actions in 2016
The need for a critical review of the intellectual property system and incentives for medical innovation (June 2016)


Brussels, 2 June 2016
 

25 Civil Society organisations, including the Medicines in Europe Forum and the International Society of Drug Bulletins, call on Member States to resist pressure from the pharmaceutical industry to eliminate critical elements of proposed European Union (EU) Council Conclusions that would improve the balance between innovation and patients' access to affordable medicines.

These Conclusions are scheduled for adoption by the Council on June 17, 2016. The Dutch EU Presidency has proposed an evaluation of EU mechanisms to encourage innovation for medicines. It now appears that specific recommendations that examine the suitability and impact of excessive intellectual property protection may be removed.


> Click here to download the Joint Statement (pdf, 122 Ko)


©ISDB, MiEF and 23 other organisations, June 2016